Search for Chemical Compounds for Pharmacotherapy of Neurofibromatosis Type 2

D. S. Stepanova; J. Chernoff; N. L. Shimanovskiy

doi:10.1007/s11094-015-1194-z

Search for Chemical Compounds for Pharmacotherapy of Neurofibromatosis Type 2

D. S. Stepanova, J. Chernoff, N. L. Shimanovskiy

Cancer Signaling and Microenvironment (CSM)

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

A murine embryonic fibroblast cell line (MEF NF2^-/-) was generated to model neurofibromatosis type 2 (NF2), a serious inherited disease for which there is no pharmacotherapeutic cure. Screening of a library of low-molecular-weight bioactive compounds using the experimental cell line MEF NF2^-/- and MEF NF2^f/f as a control cell line identified two agents, lovastatin and cerulenin, as potential candidates for NF2 pharmacotherapy.

Original language	English
Pages (from-to)	777-782
Number of pages	6
Journal	Pharmaceutical Chemistry Journal
Volume	48
Issue number	12
DOIs	https://doi.org/10.1007/s11094-015-1194-z
State	Published - Mar 1 2015

Keywords

cerulenin
chemical screening
lovastatin
neurofibromatosis type 2
pharmacotherapy

Access to Document

10.1007/s11094-015-1194-z

Cite this

@article{b55a0119115b493e87b11734c55a1923,

title = "Search for Chemical Compounds for Pharmacotherapy of Neurofibromatosis Type 2",

abstract = "A murine embryonic fibroblast cell line (MEF NF2-/-) was generated to model neurofibromatosis type 2 (NF2), a serious inherited disease for which there is no pharmacotherapeutic cure. Screening of a library of low-molecular-weight bioactive compounds using the experimental cell line MEF NF2-/- and MEF NF2f/f as a control cell line identified two agents, lovastatin and cerulenin, as potential candidates for NF2 pharmacotherapy.",

keywords = "cerulenin, chemical screening, lovastatin, neurofibromatosis type 2, pharmacotherapy",

author = "Stepanova, \{D. S.\} and J. Chernoff and Shimanovskiy, \{N. L.\}",

note = "Publisher Copyright: {\textcopyright} 2015, Springer Science+Business Media New York.",

year = "2015",

month = mar,

day = "1",

doi = "10.1007/s11094-015-1194-z",

language = "English",

volume = "48",

pages = "777--782",

journal = "Pharmaceutical Chemistry Journal",

issn = "0091-150X",

publisher = "Springer New York",

number = "12",

}

TY - JOUR

T1 - Search for Chemical Compounds for Pharmacotherapy of Neurofibromatosis Type 2

AU - Stepanova, D. S.

AU - Chernoff, J.

AU - Shimanovskiy, N. L.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - A murine embryonic fibroblast cell line (MEF NF2-/-) was generated to model neurofibromatosis type 2 (NF2), a serious inherited disease for which there is no pharmacotherapeutic cure. Screening of a library of low-molecular-weight bioactive compounds using the experimental cell line MEF NF2-/- and MEF NF2f/f as a control cell line identified two agents, lovastatin and cerulenin, as potential candidates for NF2 pharmacotherapy.

AB - A murine embryonic fibroblast cell line (MEF NF2-/-) was generated to model neurofibromatosis type 2 (NF2), a serious inherited disease for which there is no pharmacotherapeutic cure. Screening of a library of low-molecular-weight bioactive compounds using the experimental cell line MEF NF2-/- and MEF NF2f/f as a control cell line identified two agents, lovastatin and cerulenin, as potential candidates for NF2 pharmacotherapy.

KW - cerulenin

KW - chemical screening

KW - lovastatin

KW - neurofibromatosis type 2

KW - pharmacotherapy

UR - https://www.scopus.com/pages/publications/84953361572

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000353403100003&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1007/s11094-015-1194-z

DO - 10.1007/s11094-015-1194-z

M3 - Article

SN - 0091-150X

VL - 48

SP - 777

EP - 782

JO - Pharmaceutical Chemistry Journal

JF - Pharmaceutical Chemistry Journal

IS - 12

ER -

Search for Chemical Compounds for Pharmacotherapy of Neurofibromatosis Type 2

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this